The future of Qiagen NV has catapulted into uncertainty following a flurry of negative announcements. The company previewed lower-than-expected third-quarter revenue late on 7 October, stating it would reach only 3% growth, missing its 4% to 5% projection. Qiagen said the revenue shortfall is related to continued troubles in the Chinese market.
Although growth remained strong outside of China, Qiagen’s failure to deliver sales in China spooked the stock market, with company shares tumbling 17% off the back of the results and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?